RT Journal Article
SR Electronic
T1 Impact of Medical Cannabis Treatment on Healthcare Utilization in Patients with Post-traumatic Stress Disorder: A Retrospective Cohort Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.25.24317892
DO 10.1101/2024.11.25.24317892
A1 Doucette, Mitchell L.
A1 Macfarlan, D. Luke
A1 Kasabuski, Mark
A1 Chin, Junella
A1 Fisher, Emily
YR 2024
UL http://medrxiv.org/content/early/2024/11/28/2024.11.25.24317892.abstract
AB Introduction Medical cannabis is increasingly used as a therapy for managing post-traumatic stress disorder (PTSD). Patients with PTSD often have high healthcare utilization rates, particularly for acute services. This study examines the association between medical cannabis treatment and healthcare utilization among patients with PTSD.Methods We conducted a retrospective cohort study using cross-sectional data with tem-poral elements, derived from administrative records provided by Leafwell, among patients with PTSD. The cohort was defined based on medical cannabis use: the treated group included patients who had used medical cannabis for at least one year (returning for medical card renewal), while the untreated group consisted of cannabis-naive patients reporting no prior cannabis use. The primary outcomes were healthcare utilization within the past six months, including at least one urgent care visit, emergency department (ED) visit, or hospitalization related to their primary medical condition. We used inverse probability weighting with regression adjustment (IPWRA) to estimate the average treatment effect (ATE) of medical cannabis use on healthcare utilization, controlling for key demographics and health factors, including PTSD severity. Sensitivity analyses were conducted to assess the robustness of our findings.Results Among the 1,946 participants, the treated group (n = 1,261) had significantly lower healthcare utilization rates compared to the untreated group (n = 685). Using the doubly robust IPWRA model, medical cannabis treatment was associated with a significant 35.6% reduction in urgent care visits (coefficient = -0.024, Standard Error (SE) = 0.0117) and a 35.1% reduction in ED visits (coefficient = -0.027, SE = 0.0124). Hospitalization rates were 26.3% lower among the treated group but did not reach statistical significance. Sensitivity analyses utilizing alternative ATE estimation strategies displayed consistent reductions in urgent care and ED visits among cannabis users, though hospitalizations remained non-significant. Adjusting the IPWRA model’s tolerance levels strengthened the found associations while maintaining strong covariate balance. Fewer than 2% of the treated group reported an adverse event.Discussion These findings suggest that medical cannabis treatment among patients with PTSD may be associated with reduced utilization of urgent care and ED services. This relationship remains robust across multiple statistical models and sensitivity analyses, underscoring the potential role of medical cannabis in reducing acute healthcare needs in this population. Further longitudinal research is warranted to explore causality and assess its impact on hospitalization rates.Competing Interest StatementThis study was conducted using data provided by Leafwell, a Telehealth company that facilitates access to medical cannabis cards through physician diagnoses. Leafwell does not manufacture or sell cannabis products. The authors declare no direct financial interests in the production or sale of cannabis products. However, as Leafwell provides services related to medical cannabis card certifications, the authors acknowledge that the findings of this study could indirectly benefit the company.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Biomedical Research Alliance of New York (BRANY), IRB Number: IRB00000080, gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in this study are proprietary and were provided by Leafwell, a Telehealth company. Access to these data is restricted and cannot be shared publicly due to confidentiality agreements and proprietary considerations.